{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:25:10Z","timestamp":1771007110962,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T00:00:00Z","timestamp":1282003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11926-010-0127-9","type":"journal-article","created":{"date-parts":[[2010,8,16]],"date-time":"2010-08-16T06:19:23Z","timestamp":1281939563000},"page":"318-324","source":"Crossref","is-referenced-by-count":11,"title":["Biomarkers in Spondyloarthritis"],"prefix":"10.1007","volume":"12","author":[{"given":"Walter P.","family":"Maksymowych","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,17]]},"reference":[{"key":"127_CR1","first-page":"OP132","volume":"63","author":"DM Heijde van der","year":"2004","unstructured":"van der Heijde DM, Wanders A, Mielants H, et al.: Prediction of progression of radiographic damage over 4\u00a0years in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2004, 63:OP132.","journal-title":"Ann Rheum Dis"},{"key":"127_CR2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.24132","volume":"60","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP, Chiowchanwisawakit P, Clare T, et al.: Inflammatory lesions of the spine on MRI predict the development of new syndesmophytes in ankylosing spondylitis: evidence for coupling between inflammation and ankylosis. Arthritis Rheum 2009, 60:93\u2013102.","journal-title":"Arthritis Rheum"},{"key":"127_CR3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"\u2022\u2022 Rudwaleit M, Claudepierre P, Wordsworth P, et al.: Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36:801\u2013808. This was a large, open-label analysis of the efficacy and safety of adalimumab in real world practice that also examined clinical and laboratory parameters used in routine care as predictors of treatment response.","journal-title":"J Rheumatol"},{"key":"127_CR4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, et al.: Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor a blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63:665\u2013670.","journal-title":"Ann Rheum Dis"},{"key":"127_CR5","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"\u2022 Rudwaleit M, Schwarzlose S, Hilgert ES, et al.: MRI in predicting a major clinical response to anti-tumor necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008, 67:1276\u20131281. This is one of the few studies that has incorporated MRI data for inflammation into a prediction model for treatment response.","journal-title":"Ann Rheum Dis"},{"key":"127_CR6","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136\u20132146.","journal-title":"Arthritis Rheum"},{"key":"127_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ard.59.2.135","volume":"59","author":"M Bollow","year":"2000","unstructured":"Bollow M, Fischer T, Reisshauer H, et al.: Quantitative analyses of sacroiliac biopsies in spondylarthropathies: T cells and macrophages predominate in early and active sacroiliitis\u2014cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000, 59:135\u2013140.","journal-title":"Ann Rheum Dis"},{"key":"127_CR8","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar2035","volume":"8","author":"H Appel","year":"2006","unstructured":"Appel H, Loddenkemper C, Grozdanovic Z, et al.: Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006, 8:R143.","journal-title":"Arthritis Res Ther"},{"key":"127_CR9","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"RGW Lambert","year":"2007","unstructured":"Lambert RGW, Salonen D, Rahman P, et al.: Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis. Arthritis Rheum 2007, 56:4005\u20134014.","journal-title":"Arthritis Rheum"},{"key":"127_CR10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3349\/ymj.2007.48.2.218","volume":"48","author":"SY Jung","year":"2007","unstructured":"Jung SY, Park MC, Park YB, Lee SK: Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J 2007, 48:218\u2013224.","journal-title":"Yonsei Med J"},{"key":"127_CR11","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/ard.2009.120139","volume":"69","author":"DA Poddubnyy","year":"2010","unstructured":"Poddubnyy DA, Rudwaleit M, Listing J, et al.: Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 2010, 69:1338\u20131341.","journal-title":"Ann Rheum Dis"},{"key":"127_CR12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","volume":"26","author":"A Bal","year":"2007","unstructured":"Bal A, Unlu E, Bahar G, et al.: Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007, 26:211\u2013215.","journal-title":"Clin Rheumatol"},{"key":"127_CR13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/ard.2003.011023","volume":"62","author":"C Keller","year":"2003","unstructured":"Keller C, Webb A, Davis J: Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 2003, 62:1128\u20131132.","journal-title":"Ann Rheum Dis"},{"key":"127_CR14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/ard.2007.071605","volume":"67","author":"S Visvanathan","year":"2008","unstructured":"\u2022 Visvanathan S, Wagner C, Marini JC, et al.: Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008, 67:511\u2013517. This is one of the larger studies in the field and includes a multivariate analysis of cytokines and other biomarkers as predictors of treatment response. The latter is defined according to both MRI and clinical parameters of inflammation.","journal-title":"Ann Rheum Dis"},{"key":"127_CR15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/ard.2009.107649","volume":"69","author":"L Melis","year":"2010","unstructured":"\u2022 Melis L, Vandooren B, Kruithof E, et al.: Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010, 69:618\u2013623. This study compared synovial and peripheral blood expression of IL-17\/23 in RA, psoriatic arthritis, and SpA. Cytokines are examined for their associations with disease activity.","journal-title":"Ann Rheum Dis"},{"key":"127_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10067-008-1011-0","volume":"28","author":"D Wendling","year":"2009","unstructured":"Wendling D, Cedoz JP, Racadot E: Serum and synovial fluid levels of p40 IL12\/23 in spondyloarthropathy patients. Clin Rheumatol 2009, 28:187\u2013190.","journal-title":"Clin Rheumatol"},{"key":"127_CR17","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/art.23998","volume":"58","author":"M Rihl","year":"2008","unstructured":"Rihl M, Kellner H, Kellner W, et al.: Identification of interleukin-7 as a candidate disease mediator in spondylarthritis, Arthritis Rheum 2008, 58:3430\u20133435.","journal-title":"Arthritis Rheum"},{"key":"127_CR18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ard.2008.102277","volume":"69","author":"N Haroon","year":"2010","unstructured":"Haroon N, Tsui FWL, O\u2019Shea FD, et al.: From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis. Ann Rheum Dis 2010, 69:297\u2013300.","journal-title":"Ann Rheum Dis"},{"key":"127_CR19","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/art.22589","volume":"56","author":"WP Maksymowych","year":"2007","unstructured":"Maksymowych WP, Landew\u00e9 R, Conner-Spady B, et al.: Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007, 56:1846\u20131853.","journal-title":"Arthritis Rheum"},{"key":"127_CR20","first-page":"2030","volume":"35","author":"WP Maksymowych","year":"2008","unstructured":"\u2022 Maksymowych WP, Rahman P, Shojania K, et al.: Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008, 35:2030\u20132037. This report describes the associations between several biomarkers and disease activity in a placebo-controlled trial of adalimumab in AS. Disease activity is assessed according to clinical, laboratory, and MRI parameters.","journal-title":"J Rheumatol"},{"key":"127_CR21","first-page":"1753","volume":"34","author":"JH Woo","year":"2007","unstructured":"Woo JH, Lee HJ, Sung IH, Kim TH: Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007, 34:1753\u20131759.","journal-title":"J Rheumatol"},{"key":"127_CR22","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar2537","volume":"10","author":"H Appel","year":"2008","unstructured":"\u2022 Appel H, Janssen L, Listing J, et al.: Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008, 10:R125. This is one of the few studies comparing biomarker levels over time in patients on standard therapy and those receiving a TNF blocker.","journal-title":"Arthritis Res Ther"},{"key":"127_CR23","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1002\/art.20477","volume":"50","author":"B Vandooren","year":"2004","unstructured":"Vandooren B, Kruithof E, Yu DT, et al.: Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004, 50:2942\u20132953.","journal-title":"Arthritis Rheum"},{"key":"127_CR24","first-page":"1911","volume":"32","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych WP, Poole AR, Hiebert L, et al.: Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005, 32:1911\u20131917.","journal-title":"J Rheumatol"},{"key":"127_CR25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.20870","volume":"52","author":"TH Kim","year":"2005","unstructured":"Kim TH, Stone M, Payne U, et al.: Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 2005, 52:885\u2013891.","journal-title":"Arthritis Rheum"},{"key":"127_CR26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/rheumatology\/ken148","volume":"47","author":"D Vosse","year":"2008","unstructured":"\u2022 Vosse D, Landew\u00e9 R, Garnero P, et al.: Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2\u00a0years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford) 2008, 47:1219\u20131222. This prospective study examined biomarkers of cartilage turnover in a multivariate analysis of AS patients on standard therapies to determine their ability to predict joint damage.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 21","key":"127_CR27","first-page":"S16","volume":"18","author":"E Toussirot","year":"2000","unstructured":"Toussirot E, Wendling D: Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 2000, 18(Suppl 21):S16\u2013S20.","journal-title":"Clin Exp Rheumatol"},{"key":"127_CR28","first-page":"2201","volume":"26","author":"D Mitra","year":"1999","unstructured":"Mitra D, Elvins DM, Collins AJ: Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. J Rheumatol 1999, 26:2201\u20132204.","journal-title":"J Rheumatol"},{"key":"127_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/rheumatology\/38.1.21","volume":"38","author":"E Toussirot","year":"1999","unstructured":"Toussirot E, Ricard-Blum S, Dumoulin G, et al.: Relationship between urinary pyridinium crosslinks, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 1999, 38:21\u201327.","journal-title":"Rheumatology"},{"key":"127_CR30","first-page":"2236","volume":"31","author":"H Franck","year":"2004","unstructured":"Franck H, Meurer T, Hofbauer LC: Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004, 31:2236\u20132241.","journal-title":"J Rheumatol"},{"key":"127_CR31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard.2007.084426","volume":"68","author":"S Visvanathan","year":"2009","unstructured":"Visvanathan S, van der Heijde D, Deodhar A, et al.: Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:175\u2013182.","journal-title":"Ann Rheum Dis"},{"key":"127_CR32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/ard.2007.075085","volume":"67","author":"E Toussirot","year":"2008","unstructured":"Toussirot E, Dumoulin G, Saas P, et al.: Increased tartrate-resistant acid phosphatase serum levels in ankylosing spondylitis and relationship with the inflammatory process. Ann Rheum Dis 2008, 67:430\u2013431.","journal-title":"Ann Rheum Dis"},{"key":"127_CR33","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/rheumatology\/kel072","volume":"45","author":"HR Kim","year":"2006","unstructured":"Kim HR, Kim HY, Lee SH: Elevated serum levels of soluble receptor activator of nuclear factors-kappa B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 2006, 45:1197\u20131200.","journal-title":"Rheumatology (Oxford)"},{"key":"127_CR34","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","volume":"65","author":"M Vis","year":"2006","unstructured":"Vis M, Havaardsholm EA, Haugeberg G, et al.: Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF kappa B ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1495\u20131499.","journal-title":"Ann Rheum Dis"},{"key":"127_CR35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, et al.: Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156\u2013163.","journal-title":"Nat Med"},{"issue":"Suppl II","key":"127_CR36","first-page":"129","volume":"67","author":"N Wang","year":"2008","unstructured":"Wang N, Morrow S, Mallon C, Maksymowych WP: DKK-1 levels are comparably increased in patients with AS and RA, show similar decreases with anti-TNF therapy, and are not associated with markers of bone remodeling [abstract]. Ann. Rheum Dis 2008, 67(Suppl II):129.","journal-title":"Ann Rheum Dis"},{"key":"127_CR37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/art.27231","volume":"62","author":"D Daoussis","year":"2010","unstructured":"\u2022 Daoussis D, Liossis SN, Solomou EE, et al.: Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62:150\u2013158. In contrast to the Diarra et al. report [34], this study reported higher levels of DKK-1 in AS but also provided evidence that DKK-1 may be dysfunctional. Furthermore, it showed that this may be an important factor in driving new bone formation through inhibition of signalling through wingless proteins.","journal-title":"Arthritis Rheum"},{"key":"127_CR38","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/rheumatology\/ken385","volume":"47","author":"ST Choi","year":"2008","unstructured":"Choi ST, Kim JH, Kang EJ, et al.: Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 2008, 47:1775\u20131779.","journal-title":"Rheumatology (Oxford)"},{"key":"127_CR39","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar2747","volume":"11","author":"E Toussirot","year":"2009","unstructured":"\u2022\u2022 Toussirot E, Saas P, Deschamps M, et al.: Increased production of soluble CTLA-4 in patients with spondyloarthropathies correlates with disease activity. Arthritis Res Ther 2009, 11:R101. This study reported for the first time that a biomarker reflecting regulation of T-cell costimulation may reflect disease activity in SpA.","journal-title":"Arthritis Res Ther"},{"key":"127_CR40","first-page":"1846","volume":"35","author":"CH Chen","year":"2008","unstructured":"Chen CH, Liao HT, Chen HA, et al.: Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a new mediator involved in early ankylosing spondylitis. J Rheumatol 2008, 35:1846\u20131848.","journal-title":"J Rheumatol"},{"issue":"Suppl","key":"127_CR41","first-page":"1797","volume":"60","author":"FD O\u2019Shea","year":"2009","unstructured":"O\u2019Shea FD, Haroon N, Riarh R, Inman RD: A prediction model for future radiologic damage in ankylosing spondylitis based on a prospective cohort analysis [abstract]. Arthritis Rheum 2009, 60(Suppl):1797.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"127_CR42","first-page":"428","volume":"69","author":"WP Maksymowych","year":"2010","unstructured":"Maksymowych WP, Morency N, Wichuk S, et al.: Multiplex assay of a panel of 58 biomarkers in ankylosing spondylitis: identification of high priority candidates for prediction of structural damage [abstract]. Ann Rheum Dis 2010, 69(Suppl 3):428.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"127_CR43","first-page":"105","volume":"69","author":"X Baraliakos","year":"2010","unstructured":"Baraliakos X, Landewe RB, van der Heijde D, et al.: The relationship of biomarkers and radiographic progression in patients with ankylosing spondylitis treated with TNF-blockers [abstract]. Ann Rheum Dis 2010, 69(Suppl 3):105.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"127_CR44","first-page":"442","volume":"69","author":"J Sieper","year":"2010","unstructured":"Sieper J, Appel H, Rudwaleit M, et al.: Inverse correlation between serum levels of dickkopf 1 (DKK1) and new bone formation in ankylosing spondylitis patients [abstract]. Ann Rheum Dis 2010, 69(Suppl 3):442.","journal-title":"Ann Rheum Dis"},{"key":"127_CR45","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/art.24888","volume":"60","author":"H Appel","year":"2009","unstructured":"\u2022\u2022 Appel H, Ruiz-Heiland G, Listing J, et al.: Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009, 60:3257\u20133262. This study described the first evaluation of sclerostin as a biomarker for predicting radiographic progression in SpA. It also described the immunohistochemical localization data of this molecule in SpA as compared with RA patients and those with osteoarthritis.","journal-title":"Arthritis Rheum"},{"key":"127_CR46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/03009740701774941","volume":"37","author":"MC Park","year":"2008","unstructured":"Park MC, Park YB, Lee SK: Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scand J Rheumatol 2008, 37:200\u2013204.","journal-title":"Scand J Rheumatol"},{"key":"127_CR47","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.24838","volume":"61","author":"MK Vries de","year":"2009","unstructured":"\u2022 de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al.: Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009, 61:1484\u20131490. This was a large prospective study analyzing clinical and laboratory parameters used in routine care as predictors of treatment response to anti\u2013TNF-\u03b1 therapy.","journal-title":"Arthritis Rheum"},{"key":"127_CR48","first-page":"2078","volume":"34","author":"M Luc","year":"2007","unstructured":"Luc M, Gossec L, Ruyssen-Witrand A, et al.: C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis. J Rheumatol 2007, 34:2078\u20132081.","journal-title":"J Rheumatol"},{"key":"127_CR49","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10067-008-0941-x","volume":"27","author":"C Romero-S\u00e1nchez","year":"2008","unstructured":"Romero-S\u00e1nchez C, Robinson WH, Tomooka BH, et al.: Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 2008, 27:1429\u20131435.","journal-title":"Clin Rheumatol"},{"key":"127_CR50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2003.006916","volume":"63","author":"MA Stone","year":"2004","unstructured":"Stone MA, Payne U, Pacheco-Tena C, Inman RD: Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004, 63:84\u201387.","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0127-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0127-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0127-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:49:53Z","timestamp":1559436593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0127-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,17]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["127"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0127-9","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,17]]}}}